Based on the key indicators related to SpringWorks Therapeutics' liquidity, profitability, solvency, and operating efficiency, SpringWorks Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, SpringWorks Therapeutics' Property Plant And Equipment Net is fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 217.2 M in 2025, whereas Cash is likely to drop slightly above 58.7 M in 2025. Key indicators impacting SpringWorks Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for SpringWorks Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor SpringWorks Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in SpringWorks Therapeutics.
Please note, the imprecision that can be found in SpringWorks Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SpringWorks Therapeutics. Check SpringWorks Therapeutics' Beneish M Score to see the likelihood of SpringWorks Therapeutics' management manipulating its earnings.
SpringWorks Therapeutics Stock Summary
SpringWorks Therapeutics competes with Relay Therapeutics, Stoke Therapeutics, Pliant Therapeutics, Black Diamond, and Arvinas. SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Springworks Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Cash flow analysis captures how much money flows into and out of SpringWorks Therapeutics. It measures of how well SpringWorks is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money SpringWorks Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money SpringWorks had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what SpringWorks Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining SpringWorks Therapeutics's current stock value. Our valuation model uses many indicators to compare SpringWorks Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SpringWorks Therapeutics competition to find correlations between indicators driving SpringWorks Therapeutics's intrinsic value. More Info.
SpringWorks Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, SpringWorks Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SpringWorks Therapeutics' earnings, one of the primary drivers of an investment's value.
SpringWorks Therapeutics Systematic Risk
SpringWorks Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SpringWorks Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on SpringWorks Therapeutics correlated with the market. If Beta is less than 0 SpringWorks Therapeutics generally moves in the opposite direction as compared to the market. If SpringWorks Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SpringWorks Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SpringWorks Therapeutics is generally in the same direction as the market. If Beta > 1 SpringWorks Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in SpringWorks Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various SpringWorks Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of SpringWorks Therapeutics growth as a starting point in their analysis.
SpringWorks Therapeutics March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SpringWorks Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SpringWorks Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of SpringWorks Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing SpringWorks Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SpringWorks Therapeutics's daily price indicators and compare them against related drivers.
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.